Ovarian cancer patients with BRCA1/2 mutations are known to respond better to platinum‐based chemotherapies and have longer overall survivals2, 23 and they also benefit from PARP inhibitor which is currently the most important targeted therapy for HGSOC patients.24 The high prevalence of BRCA1/2 mutations, most of which were from germline samples, highlighted the importance of routine BRCA1/2 testing for Chinese ovarian cancer patients. This evidence concerns the gene BRCA1 and ovarian cancer.